PURGO BIOLOGICS Inc.

Purgo Biologics Inc. specializes in three primary categories: monofilament sutures made from polyolefin and fluoropolymer, including a polytetrafluoroethylene (PTFE) suture for surgical use; dental bone matrix implants derived from animal sources; and pliable-polymer dental regeneration membranes that are non-bioabsorbable. These devices are designed for surgical and dental applications, addressing wound closure, bone regeneration, and tissue integration.

Purgo Biologics Inc. is headquartered in South Korea. While the company’s location determines its primary regulatory jurisdiction (e.g., adherence to Korean medical device regulations), its devices are also listed in international registries like EUDAMED and the FDA’s 510(k) and UDI systems. This reflects its global market presence and compliance with multiple regulatory frameworks, including EU Class II/III and Class IIa classifications.

Purgo Biologics Inc.’s devices are listed in EUDAMED (the EU’s medical device registry), FDA 510(k) (for premarket notifications in the U.S.), and the FDA’s Unique Device Identifier (UDI) system. These registries are critical because they demonstrate compliance with respective regulatory bodies, facilitate transparency for healthcare providers, and enable tracking of devices throughout their lifecycle for safety and performance monitoring.

Under EU regulations, Purgo Biologics Inc.’s devices fall into Class II, Class III, and Class IIa classifications, depending on their risk level and intended use. For example, sutures like the TBS PTFE Suture are typically Class II due to their moderate risk, while dental bone matrix implants (e.g., THE Graft) may qualify as Class III due to higher risks associated with bone regeneration. In the U.S., these devices are submitted via 510(k) premarket notifications, which assess their safety and effectiveness compared to predicate devices.